Clinical Trials Sponsored by Pierre Fabre Pharma Austria

Total 14 results

Pierre Fabre Pharma GmbH
Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (BERING)

Melanoma Stage IV | Melanoma Stage III

Austria, Germany, Switzerland
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment (BERING-CRC)

Metastatic Colorectal Carcinoma

Austria, Germany
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Active, not recruiting

Real-life Pan-HER-blockade With Neratinib (ELEANOR)

Breast Neoplasm

Austria, Germany, Switzerland
Pierre Fabre Medicament
Pierre Fabre Pharma GmbH

Completed

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

NSCLC

Germany
Pierre Fabre Pharma AG

Completed

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). (Real-CHOICE)

Iron-Deficiency Anemia | Iron-Deficiency

Switzerland
Pierre Fabre Pharma GmbH
iOMEDICO AG

Completed

Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer | Non Small Cell Lung Carcinoma

Germany
Pierre Fabre Pharma GmbH
Winicker Norimed GmbH

Completed

Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria (StepUp)

Breast Cancer | Non-Small-Cell Lung Cancer

Germany, Austria
Johannes Gutenberg University Mainz
Pierre Fabre Pharma GmbH

Completed

Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer (VinoMetro)

Metastatic Breast Cancer

Germany
Pierre Fabre Pharma GmbH
DocCheck Medical Services GmbH

Completed

JAVLOR® Online Non-Interventional Trial (JONAS-1)

Transitional Cell Carcinoma

Germany
Charite University, Berlin, Germany
Bristol-Myers Squibb; Pierre Fabre Pharma GmbH

Unknown

Study for Patients With Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Germany
AIO-Studien-gGmbH
Universitätsklinikum Hamburg-Eppendorf; Merck Serono GmbH, Germany; Pierre Fabre...

Recruiting

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF)

Colorectal Cancer | Colon Cancer | BRAF V600 Mutation | BRAF V600E | Localized Cancer

Germany
University Hospital, Brest
Roche Farma, S.A; Pierre Fabre Medicament; Groupe Francais De Pneumo-Cancerologie

Completed

Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer (VinMetAtezo)

Non-small Cell Lung Cancer

France
UNICANCER
Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences; Roche Pharma... and other collaborators

Recruiting

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 (ESME-MBC)

Metastatic Breast Cancer

France
Universidade do Algarve
University of Huelva; OKM Química Ortopédica S.L.; Lola - J. Andrade Ferreira... and other collaborators

Completed

Impact of Therapeutic Footwear and Plantar Orthoses on Diabetic Neuropathic Foot in Quality of Life and Functionality

Diabetes Mellitus, Type 2 | Diabetic Peripheral Neuropathy

Portugal

Clinical Trials Sponsored by Pierre Fabre Pharma Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations